Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation

J. I. Lee, H. W. Kim, J. Y. Kim, S. J. Bae, D. J. Joo, K. H. Huh, Y. H. Fang, J. H. Jeong, M. S. Kim, Y. S. Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Improving human islet transplantation is often limited by the shortage of donors and the side effects of immunosuppressive agents. If immunoisolation is properly used, it can overcome these obstacles. Because artificial materials are adopted in this technique, however, there are still multiple issues with biocompatibility and foreign body reactions. We developed a chondrocyte microencapsulated immunoisolated islet (CMI-islet) that allows living cells to act as the immunoisolating material. To manufacture CMI-islets for xenotransplantation, isolated rat pancreatic islets were placed on low cell-binding culture dishes. Subsequently, expanded canine auricular cartiage primary cells were seeded on these dishes at a high density and maintained in a suspended state via a shaking culture system. Morphological evaluations showed good islet viability and a clear progression of the islet- encapsulation events. When the cells were challenged with glucose, they were able to secrete sufficient insulin according to glucose concentrations. The CMI-islets responded better to the glucose challenge than did nude pancreatic islets and created better glucose-insulin feedback regulation. Moreover, insulin secretion into the culture medium was confirmed over a period of 100 days, showing the survival and secretory capacity of the CMI-islet cells. By microencapsulating pancreatic islets with recipient ear cartilage cells, long-term insulin secretion can be maintained and the response to glucose challenges improved. This new immunodelusion technology differs from other immunoisolation techniques in that the donor tissue is enclosed with the recipient's tissue, thus allowing the transplanted cells to be recognized as recipient cells. This microencapsulation method may lead to developing viable xenotransplantation techniques that do not use immunosuppressive drugs.

Original languageEnglish
Pages (from-to)1091-1094
Number of pages4
JournalTransplantation Proceedings
Volume44
Issue number4
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

Ear Cartilage
Drug Compounding
Islets of Langerhans
Canidae
Glucose
Insulin
Heterologous Transplantation
Immunosuppressive Agents
Chondrocytes
Foreign-Body Reaction
Islets of Langerhans Transplantation
Culture Media
Cell Culture Techniques
Tissue Donors
Technology
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Lee, J. I. ; Kim, H. W. ; Kim, J. Y. ; Bae, S. J. ; Joo, D. J. ; Huh, K. H. ; Fang, Y. H. ; Jeong, J. H. ; Kim, M. S. ; Kim, Y. S. / Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation. In: Transplantation Proceedings. 2012 ; Vol. 44, No. 4. pp. 1091-1094.
@article{b9537acd4caf407a9602cbb58ad5b181,
title = "Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation",
abstract = "Improving human islet transplantation is often limited by the shortage of donors and the side effects of immunosuppressive agents. If immunoisolation is properly used, it can overcome these obstacles. Because artificial materials are adopted in this technique, however, there are still multiple issues with biocompatibility and foreign body reactions. We developed a chondrocyte microencapsulated immunoisolated islet (CMI-islet) that allows living cells to act as the immunoisolating material. To manufacture CMI-islets for xenotransplantation, isolated rat pancreatic islets were placed on low cell-binding culture dishes. Subsequently, expanded canine auricular cartiage primary cells were seeded on these dishes at a high density and maintained in a suspended state via a shaking culture system. Morphological evaluations showed good islet viability and a clear progression of the islet- encapsulation events. When the cells were challenged with glucose, they were able to secrete sufficient insulin according to glucose concentrations. The CMI-islets responded better to the glucose challenge than did nude pancreatic islets and created better glucose-insulin feedback regulation. Moreover, insulin secretion into the culture medium was confirmed over a period of 100 days, showing the survival and secretory capacity of the CMI-islet cells. By microencapsulating pancreatic islets with recipient ear cartilage cells, long-term insulin secretion can be maintained and the response to glucose challenges improved. This new immunodelusion technology differs from other immunoisolation techniques in that the donor tissue is enclosed with the recipient's tissue, thus allowing the transplanted cells to be recognized as recipient cells. This microencapsulation method may lead to developing viable xenotransplantation techniques that do not use immunosuppressive drugs.",
author = "Lee, {J. I.} and Kim, {H. W.} and Kim, {J. Y.} and Bae, {S. J.} and Joo, {D. J.} and Huh, {K. H.} and Fang, {Y. H.} and Jeong, {J. H.} and Kim, {M. S.} and Kim, {Y. S.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.transproceed.2012.02.015",
language = "English",
volume = "44",
pages = "1091--1094",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

Lee, JI, Kim, HW, Kim, JY, Bae, SJ, Joo, DJ, Huh, KH, Fang, YH, Jeong, JH, Kim, MS & Kim, YS 2012, 'Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation', Transplantation Proceedings, vol. 44, no. 4, pp. 1091-1094. https://doi.org/10.1016/j.transproceed.2012.02.015

Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation. / Lee, J. I.; Kim, H. W.; Kim, J. Y.; Bae, S. J.; Joo, D. J.; Huh, K. H.; Fang, Y. H.; Jeong, J. H.; Kim, M. S.; Kim, Y. S.

In: Transplantation Proceedings, Vol. 44, No. 4, 01.05.2012, p. 1091-1094.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Microencapsulation of pancreatic islets with canine ear cartilage for immunoisolation

AU - Lee, J. I.

AU - Kim, H. W.

AU - Kim, J. Y.

AU - Bae, S. J.

AU - Joo, D. J.

AU - Huh, K. H.

AU - Fang, Y. H.

AU - Jeong, J. H.

AU - Kim, M. S.

AU - Kim, Y. S.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Improving human islet transplantation is often limited by the shortage of donors and the side effects of immunosuppressive agents. If immunoisolation is properly used, it can overcome these obstacles. Because artificial materials are adopted in this technique, however, there are still multiple issues with biocompatibility and foreign body reactions. We developed a chondrocyte microencapsulated immunoisolated islet (CMI-islet) that allows living cells to act as the immunoisolating material. To manufacture CMI-islets for xenotransplantation, isolated rat pancreatic islets were placed on low cell-binding culture dishes. Subsequently, expanded canine auricular cartiage primary cells were seeded on these dishes at a high density and maintained in a suspended state via a shaking culture system. Morphological evaluations showed good islet viability and a clear progression of the islet- encapsulation events. When the cells were challenged with glucose, they were able to secrete sufficient insulin according to glucose concentrations. The CMI-islets responded better to the glucose challenge than did nude pancreatic islets and created better glucose-insulin feedback regulation. Moreover, insulin secretion into the culture medium was confirmed over a period of 100 days, showing the survival and secretory capacity of the CMI-islet cells. By microencapsulating pancreatic islets with recipient ear cartilage cells, long-term insulin secretion can be maintained and the response to glucose challenges improved. This new immunodelusion technology differs from other immunoisolation techniques in that the donor tissue is enclosed with the recipient's tissue, thus allowing the transplanted cells to be recognized as recipient cells. This microencapsulation method may lead to developing viable xenotransplantation techniques that do not use immunosuppressive drugs.

AB - Improving human islet transplantation is often limited by the shortage of donors and the side effects of immunosuppressive agents. If immunoisolation is properly used, it can overcome these obstacles. Because artificial materials are adopted in this technique, however, there are still multiple issues with biocompatibility and foreign body reactions. We developed a chondrocyte microencapsulated immunoisolated islet (CMI-islet) that allows living cells to act as the immunoisolating material. To manufacture CMI-islets for xenotransplantation, isolated rat pancreatic islets were placed on low cell-binding culture dishes. Subsequently, expanded canine auricular cartiage primary cells were seeded on these dishes at a high density and maintained in a suspended state via a shaking culture system. Morphological evaluations showed good islet viability and a clear progression of the islet- encapsulation events. When the cells were challenged with glucose, they were able to secrete sufficient insulin according to glucose concentrations. The CMI-islets responded better to the glucose challenge than did nude pancreatic islets and created better glucose-insulin feedback regulation. Moreover, insulin secretion into the culture medium was confirmed over a period of 100 days, showing the survival and secretory capacity of the CMI-islet cells. By microencapsulating pancreatic islets with recipient ear cartilage cells, long-term insulin secretion can be maintained and the response to glucose challenges improved. This new immunodelusion technology differs from other immunoisolation techniques in that the donor tissue is enclosed with the recipient's tissue, thus allowing the transplanted cells to be recognized as recipient cells. This microencapsulation method may lead to developing viable xenotransplantation techniques that do not use immunosuppressive drugs.

UR - http://www.scopus.com/inward/record.url?scp=84860731250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860731250&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2012.02.015

DO - 10.1016/j.transproceed.2012.02.015

M3 - Article

C2 - 22564633

AN - SCOPUS:84860731250

VL - 44

SP - 1091

EP - 1094

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -